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A severe mitochondrial protein synthesis defect in myoblasts from a patient with mitochondrial myopathy
was transferred with myoblast mitochondria into two genetically unrelated mitochondrial DNA (mtDNA)-less
human cell lines, pointing to an mtDNA alteration as being responsible and sufficient for causing the disease.
The transfer of the defect correlated with marked deficiencies in respiration and cytochrome c oxidase activity
of the transformants and the presence in their mitochondria of mtDNA carrying a tRNALYS mutation. Fur-
thermore, apparently complete segregation of the defective genotype and phenotype was observed in the
transformants derived from the heterogeneous proband myoblast population, suggesting that the mtDNA
heteroplasmy in this population was to a large extent intercellular. The present work thus establishes a direct
link between mtDNA alteration and a biochemical defect.
The genetic analysis of mitochondrial diseases has been
complicated by the existence of dual control by nuclear and
mitochondrial DNA (mtDNA) of mitochondrion formation
and by the interplay of the two genomes in this process (3).
Another difficulty in the study of the diseases associated
with mtDNA mutations has been the variable degree of
penetrance of the defect (25, 27, 32). This variability reflects
the frequent coexistence in the same individual of mutated
and nonmutated mtDNA in varying proportions, often with
tissue-to-tissue differences (11-13, 23, 27, 29, 34), as well as
the influence of the nuclear background in the phenotypic
manifestation of the mtDNA-encoded defect (15, 27, 32).
Also, the molecular dissection of the defect has been hin-
dered by the pleiomorphic character of the clinical syn-
dromes and the striking tissue specificity of the mitochon-
drial dysfunction (5, 8, 20, 31).
We have recently developed novel approaches for mito-
chondrion-mediated transformation of human cells which
can find application in the genetic and molecular analysis of
mitochondrial diseases. In particular, several human cell
lines completely devoid of mtDNA (p°) have been isolated
by long-term exposure of the cells to low concentrations of
ethidium bromide (15). Owing to the lack of a functional
respiratory chain, these cell lines have become auxotrophic
for pyrimidines and pyruvate. Loss of either of these two
requirements has been used as a selectable marker for the
repopulation of the human p0 cell lines with exogenous
mitochondria from different human sources (15).
In the present study, the methodology described above
was utilized to investigate the genetic and molecular basis of
a mitochondrial protein synthesis defect found in myoblasts
from a patient affected by a mitochondrial myopathy. The
results clearly show (i) that the genetic defect responsible for
the protein synthesis alteration could be transferred to
different human mtDNA-less cell lines with the patient's
mitochondria, and therefore resided in mtDNA; (ii) that the
* Corresponding author.
transformants obtained with different myoblasts from the
proband contained either mutated or wild-type mtDNA,
pointing to mtDNA heteroplasmy in the myoblasts which
was probably to great extent intercellular; and (iii) that the
occurrence of the protein synthesis alteration in the trans-
formants was correlated with a marked respiratory defi-
ciency. Furthermore, DNA sequence analysis revealed the
presence of the tRNALYS mutation, recently found in pa-
tients suffering from myoclonic epilepsy and ragged red fiber
(MERRF) syndrome (27), in the mtDNA of the transfor-
mants derived from the defective myoblasts of the proband.
MATERIALS AND METHODS
Cell lines and media. The p°206 cell line (15), a derivative
of 143B.TK- cells, was grown in Dulbecco modified Eagle
medium (DMEM) with 4.5 mg of glucose per ml, supple-
mented with 5% fetal bovine serum (FBS), 50 ,ug of uridine
per ml, and 100 ,ug of 5-bromodeoxyuridine (BrdU) per ml.
The p°701.2a cell line was obtained from the simian virus 40
T-antigen gene-transformed derivative (701.2.8c [33a]) of the
human fibroblast strain GM701 (10) by long-term exposure to
a low concentration of ethidium bromide (14a). It was grown
in DMEM with 10% FBS and 50 ,ug of uridine per ml. The
p°13.1 cell line was obtained by long-term exposure to
ethidium bromide of an adenine phosphoribosyltransferase-
less mutant of 143B.TK- (isolated by two-step selection in
the presence of 8-azaadenine [la]). It was grown in DMEM
with 10% FBS, 50 pug of uridine per ml, and 50 ,ug of
8-azaadenine per ml. 143B.TK- cells were grown as previ-
ously described (15).
Myoblast cultures and isolation of myoblast clones. Mass
myoblast cultures were established by a previously estab-
lished procedure (16), using muscle biopsy specimens from
the proband and from four normal adult individuals. Myo-
blast clones were isolated as previously reported (17) by
plating a mass myoblast culture at a low density (-200 cells
per 10-cm dish) in conditioned medium, identifying the
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FIG. 1. Pedigree of the family of the proband analyzed in this work. Symbols: 0, MERRF syndrome; C], mitochondrial myopathy; 0,
X, ragged red fibers and/or other laboratory abnormalities; 0, 0, apparent absence of clinical manifestations; Diagonal lines indicate deaths.
P, Proband; R, relative analyzed in the present work. See text for details.
myogenic colonies by the appearance of initial fusion, and
trypsinizing them in a glass ring.
Mitochondrion-mediated transformation. p0 cell transfor-
mation by cytoplast fusion was done as previously described
(15). Approximately 6,000 proband myoblasts from a mixed
culture of five clones were enucleated (microscopic inspec-
tion of the cytoplast preparation revealed the great efficiency
of the enucleation step [>90%]) and fused to -2 x 106 p°206
cells, and transformants were isolated in DMEM supple-
mented with 5% dialyzed FBS and 100 ,ug of BrdU per ml. In
other experiments, two such transformants were fused to
p°13.1 cells as detailed in the text, using DMEM supple-
mented with 10% dialyzed FBS and 50 ,ug of 8-azaadenine
per ml as a selective medium. In still other experiments,
cytoplasts from several hundred to several thousand cells of
each of five myoblast clones from the proband (1 to 5) were
fused to a 200- to 2,000-fold excess of p°206 cells or p°701.2a
cells, and transformants were isolated in DMEM with 5%
dialyzed FBS.
Mitochondrial protein synthesis analysis. Samples of mass
myoblast cultures from the proband or control individuals,
of a mixed culture of five myoblast clones, or of individual
transformants were labeled with [35S]methionine (1,000 Ci/
mmol, 125 to 500 uCi/ml) for 1.2 to 2 h, as detailed in the
figure legends, in the presence of 100 ,ug of emetine per ml in
methionine-free DMEM supplemented with 10% dialyzed
FBS. 143B cells were similarly labeled for 1.2 h. After the
labeling, 2 volumes of complete DMEM were added, and the
cells were then washed once with DMEM and twice with
buffered saline lacking Mg2' and Ca2+ (TD), trypsinized,
washed twice with TD, and finally resuspended in TD
containing 1 mM phenylmethylsulfonyl fluoride and lysed
with 1% sodium dodecyl sulfate (SDS). In some experi-
ments, cells were labeled in 16-mm microwells, washed, and
directly lysed in 10 mM Tris (pH 7.3)-0.1 mM EDTA-1 mM
phenylmethylsulfonyl fluoride containing 1% SDS. Samples
of the various cell suspensions were run on SDS-exponential
polyacrylamide gradient gels (7). In some experiments, a
sample of an SDS lysate of the mitochondrial fraction from
2-h [35S]methionine-labeled HeLa cells, prepared as previ-
ously described (6), was run in parallel.
DNA analysis. Total DNA was prepared from cells by
using an Applied Biosystems 340A DNA extractor. Equal
samples were digested with restriction endonucleases as
recommended by the suppliers, electrophoresed in a 0.7%
agarose gel (XbaI or NcoI digests) or in a 5% polyacrylamide
gel (MboI digest), and transferred by capillarity or electro-
blotted onto a Nytran nylon membrane (0.2-,um pore size;
Schleicher & Schuell). The XbaI and Ncol blots were
probed with total HeLa cell mtDNA, 32p labeled by random
priming (9). The MboI blot was probed with the mtDNA
clone mpl8.XK76, containing the 1,097-bp KpnI-XhoI frag-
ment of HeLa mtDNA between positions 14956 and 16053 of
the Cambridge sequence (1) inserted in the KpnI and Sall
sites of M13mpl8 (14a), 32p labeled by random priming. For
the polymerase chain reaction, samples of total cell DNA (10
to 300 ng) were processed in a thermal cycler with Taq
polymerase (Amersham) and oligonucleotides corresponding
to the light strand between positions 8100 and 8117 and to the
heavy strand between positions 8392 and 8372 as primers. A
light-strand primer corresponding to positions 8263 to 8283
was used for sequencing by the dideoxynucleotide-chain
termination method (26).
02 consumption and COX measurements. 02 consumption
was measured with a Gilson 5/6 oxygraph on two to four
samples of 2 x 106 to 5 x 106 cells in 1.85 ml of DMEM
lacking glucose, supplemented with 5% dialyzed calf serum.
Cytochrome c oxidase (COX) activity was measured in
duplicate to quadruplicate on two to three samples of iso-
lated mitochondrial fraction as previously described (28).
The mtDNA concentration of these samples was determined
by dot-blot analysis as described elsewhere (15).
Chromosome analysis. Cells were arrested in metaphase by
treatment with 0.05 ,ug of colchicine per ml for 3 to 5 h or
with 0.1 ,ug of vinblastine sulfate per ml for 15 to 22 h.
Karyotype analysis was done as described previously (18).
RESULTS
Protein synthesis defect in proband myoblasts. Figure 1
shows the pedigree of the family to which the proband (P)
belonged (4). In this family, two members exhibited a typical
MERRF syndrome, with myoclonus and episodes of gener-
alized tonic-clonic seizures, progressive myopathy with
ragged red fibers in the muscle biopsy specimen, deafness,
and cerebellar abnormalities. Other members, including the
proband, exhibited mainly myopathy symptoms, ragged red
fibers, lactic acidosis, and electromyogram abnormalities.
Other members had no obvious clinical symptoms but some
laboratory signs of disease, such as ragged red fibers, lactic
acidosis, and electrocardiogram or electroencephalogram
abnormalities. Finally, other members appeared normal at
the clinical and laboratory examination. All affected mem-
bers were related through maternal lineages. The clinical and
biochemical characterization of the pedigree will be reported
elsewhere (4a).
A histochemical analysis of a muscle biopsy specimen
from the proband had previously revealed the presence of
ragged red fibers (about 40% of the fibers) and COX-negative
and succinate dehydrogenase-positive fibers (about 30% of
the fibers) (4a). Furthermore, a Southern blot analysis of the
muscle DNA had failed to show the presence of any gross
deletions of mtDNA. In the present work, a mass myoblast
culture from the proband was tested for mitochondrial
protein synthesis, in parallel with mass myoblast cultures
from three normal individuals. The pattern of the mitochon-
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FIG. 2. Myoblast cultures from the proband exhibit an abnormal
pattern of mitochondrial protein synthesis. Shown are fluorograms,
after electrophoresis through SDS-polyacrylamide gradient gels, of
the mitochondrial translation products labeled with [35S]methionine
in mass myoblast cultures from the proband (P) and three different
normal individuals (Cl, C2, and C3) and in HeLa cells (a) and in a
culture of mixed myoblast clones from the proband (P) and in HeLa
cells (b). The cultures were labeled with [35S]methionine in the
presence of emetine (for 2 h in panel a and 1.6 h in panel b), and
samples of total cell lysates of myoblast cultures (15 ,ug of protein in
panel a and 48 ,ug in panel b) or of a lysate of the mitochondrial
fraction (HeLa cells) were run through SDS-polyacrylamide gradi-
ent gels. COI, COII, and COIII: subunits I, II, and III of COX;
ND1, ND2, ND3, ND4, ND4L, ND5, and ND6, subunits 1, 2, 3, 4,
4L, 5, and 6 of the respiratory chain NADH dehydrogenase; A6 and
A8, subunits 6 and 8 of the H+-ATPase; CYTb, apocytochrome B.
drial translation products from the proband was indistin-
guishable from that of the three control myoblast cultures,
except for the presence of a band migrating slightly faster
than ND4 (Fig. 2a, asterisk). Figure 2a also shows the
mitochondrial translation pattern from HeLa cells, which
differs from that of other human cells for a previously
described ND3 polymorphism (22). That the abnormal pat-
tern of mitochondrial protein synthesis observed in the mass
myoblast culture from the proband was due to the predom-
inant myoblasts in the culture and not to fibroblasts was
shown by the experiment illustrated in Fig. 2b. In this
experiment, the mitochondrial translation products of a
mixture of five myoblast clones isolated from the mass
myoblast culture were analyzed in an SDS-polyacrylamide
gel, in parallel with the mitochondrial translation products of
HeLa cells. The pattern from the proband myoblast clones
again exhibited the abnormal band migrating faster than
ND4, as well as two minor abnormal bands (indicated by
small arrows).
Phenotype transfer with proband mitochondria. To inves-
tigate whether the abnormal pattern of mitochondrial protein
synthesis observed in the proband myoblasts was due to an
mtDNA or a nuclear DNA mutation, we fused enucleated
cells (cytoplasts) from the proband myoblast clone mixture,
in the presence of polyethylene glycol, with a large excess of
the p°206 derivative of the BrdU-resistant 143B.TK- cells
(15). Many colonies of presumptive transformants were
observed after 10 days of growth of the cell fusion mixture in
medium containing BrdU and lacking uridine. In this me-
dium, only fusion products of myoblast cytoplasts and p°206
cells were expected to survive, since p°206 cells would not
grow in the absence of uridine and, on the other hand, any
residual nonenucleated myoblasts or hybrids between these
and p°206 cells would be killed by BrdU, converted to its
toxic phosphorylated derivative by the thymidine kinase
encoded in the myoblast nucleus. A karyotype analysis of
two transformants (pT1, pT3) revealed ranges of chromo-
some numbers (72 to 93, 76 to 86) very similar to that of
p°206 cells (70 to 97), confirming their cybrid nature.
Five cybrid clones (pT1 to pT5) were tested for mitochon-
drial protein synthesis. Two of the clones, pTl and pT4,
exhibited a pattern of mitochondrial translation products
with the same abnormalities observed in the proband myo-
blasts, whereas the three remaining transformants exhibited
a normal pattern (Fig. 3a). A transformant obtained by
fusion of p0206 cells with cytoplasts from a normal individual
(C4) also showed a normal protein synthesis pattern. These
findings provided the first evidence indicating that the pro-
tein synthesis defect was due to an mtDNA mutation. A
plausible interpretation of the results was that the mtDNA
mutation was heteroplasmic and that this heteroplasmy was
to great extent intercellular, some myoblasts containing
exclusively or mainly defective mtDNA, and others contain-
ing exclusively or mainly normal mtDNA. However, selec-
tion phenomena during the growth of the myoblasts and of
the transformants could have played a role in the final
genotype and phenotype of the transformants. On the other
hand, the data did not exclude the possibility that the
phenotypic heterogeneity of the transformants was due to
nuclear heterogeneity of the p°206 recipient cells. To test the
latter possibility, we did experiments in which one defective
transformant, pTl, and one apparently normal transformant,
pT3, were used as mitochondrial donors in a second cycle of
transformation experiments. In these experiments, another
p0 cell line, p°13.1, derived as described elsewhere (14a)
from an adenine phosphoribosyltransferase-less mutant of
143B.TK- by long-term exposure to a low concentration of
ethidium bromide, was used as a recipient. The 8-azaadenine
resistance of this cell line provided a convenient selectable
marker to discriminate between the mitochondrial transfor-
mants and any residual nonenucleated p0206 transformants
or hybrids of these with p°13.1, since the latter were ex-
pected to be sensitive to the drug. In two fusion experiments
with -1.5 x 105 pTl or pT3 cells and a 10-fold excess of
p°13.1 cells, 10 or 9 transformant colonies, respectively,
were isolated in selective medium represented by DMEM
supplemented with 50 ,ug of 8-azaadenine per ml. In a control
experiment with 3.1 x 106 cells of a p°206 transformant
derived from a proband myoblast clone (no. 2, see below),
no 8-azaadenine-resistant spontaneous mutants appeared
during a 3-week culture in the presence of 50 ,ug of the drug
per ml. This experiment strongly argued against the possi-
bility of the putative p°13.1 transformants being instead
spontaneous 8-azaadenine-resistant mutants of the p°206
transformants. Five p°13.1 transformants obtained with pTl,
when tested for mitochondrial protein synthesis, revealed a
defective pattern (Fig. 4), with the characteristic abnormal
bands first observed in the myoblasts. Similarly, five p°13.1
transformants obtained with pT3 showed a normal pattern of
mitochondrial translation products. These experiments thus
clearly showed that the basis for the phenotypic heteroge-
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FIG. 3. Transformants obtained by mitochondrion transfer from proband myoblasts into human p0 cells are either defective in
mitochondrial protein synthesis and respiratory capacity or have a normal phenotype. Panel a shows the pattern of mitochondrial translation
products (1.3 h of labeling, 30 Fg of protein run on gel) and panel c shows the rate Of 02 consumption and the level of COX activity (with error
bars representing two standard errors) in five mitochondrial transformants (pT1 to pT5) generated from p°206 cells by fusion with cytoplasts
from a mixture of five myoblast clones from the proband (Fig. 2), in one p°206 transformant (cT1) obtained with myoblasts from a normal
individual (C4), and, for comparison, in HeLa cells and 143B cells. Panel b shows the protein synthesis pattern (1.3 h of labeling, 10 ,ug of
protein run on gel) and panel d shows the rate of 02 consumption and the level of COX activity in p°206 transformants obtained with five
additional individual myoblast clones from the proband (clones 1 to 5), in two p°701.2a transformants obtained with myoblast clone 2, and,
for comparison, in 143B cells. Transformants were tested for mitochondrial protein synthesis, 02 consumption, and COX activity 4 to 6
weeks, 8 to 12 weeks, and 8 to 14 weeks, respectively, after fusion. Abbreviations are defined in the legend to Fig. 2.
neity of the transformants resided in the mtDNA hetero-
plasmy of the proband myoblasts.
The experiments described above, in which two of five
transformants analyzed revealed an altered protein synthesis
pattern, did not provide precise information concerning the
proportion of myoblasts with exclusively or predominantly
defective mtDNA in the myoblast clone mixture tested. An
estimate of the frequency of the defective myoblasts was
provided by another experiment in which five additional
myoblast clones, isolated independently from the original
myoblast culture, were analyzed individually. After cyto-
plasts from each one of clones 1 to 5 were fused to a large
excess of p°206 cells, several transformants were isolated.
Karyotype analysis of four transformants revealed a range of
chromosome numbers (69 to 90) very similar to that of p°206
(70 to 97), as expected for cybrids. The original clone 2 and
two transformants produced with it and one transformant
obtained with each one of the other clones were analyzed for
-I
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FIG. 4. p0 cell transformants with altered or normal mitochon-
drial protein synthesis pattern transfer their phenotype to p°13.1
cells with their mitochondria. Shown is the fluorogram after elec-
trophoresis through an SDS-polyacrylamide gradient gel of the
mitochondrial translation products labeled with [35S]methionine for
1.3 h in five transformants obtained by fusion of p013.1 cells with
cytoplasts from pTl cells and five transformants obtained by fusion
of p°13.1 cells with cytoplasts from pT3 cells (Fig. 3a). Samples of
SDS lysates containing 3.4 p.g of protein were run on the gel.
Transformants were tested for mitochondrial protein synthesis 6
weeks after fusion. Abbreviations are defined in the legend to Fig. 2.
mitochondrial protein synthesis. Three of the clones, 2, 3,
and 5, produced transformants exhibiting an altered protein
synthesis pattern, while the remaining two clones generated
transformants exhibiting a normal pattern (Fig. 3b). Note
that the original clone 2 myoblasts also produced an altered
pattern of mitochondrial translation products. With the
obvious qualifications imposed by the limited number of
clones analyzed, this experiment, together with the previous
one, thus suggested that about 50% of the myoblast clones
were derived from myoblasts with exclusively or predomi-
nantly defective mtDNA. This may be an underestimate of
the proportion of the defective myoblasts in the original
muscle culture, considering the probable selective advantage
for clonal growth and for transforming capacity of the
myoblasts with predominantly wild-type mtDNA. Myoblast
clone 2 was also used to transform another p0 human cell
line, p°701.2a, genetically unrelated to 143B.TK-, which
exhibited the uridine and pyruvate dependence previously
shown for p0206 and p°101 (2, 15). Several transformants
were obtained from p°701.2a by fusion with cytoplasts from
clone 2 and selection in medium not supplemented with
uridine. In this medium, only cybrids between clone 2
myoblasts and p°701.2a cells and possibly hybrids involving
any residual nonenucleated myoblasts were expected to
survive. Karyotype analysis of two transformants (pT71,
pT72) revealed chromosome numbers (69 to 108, 85 to 109)
higher than the range of values observed in p0701.2a cells (60
to 68), although in general lower than the number of chro-
mosomes expected for hybrids (-110). In view of the high
frequency of enucleation (>90%) and of the usually much
greater efficiency of cybrid versus hybrid formation, it is
likely that the isolated transformants represented cybrids
with an increased parental (701.2.8c) chromosome number.
The pT71 and pT72 transformants were analyzed for mito-
chondrial protein synthesis, and they exhibited the same
alterations of the mitochondrial translation products ob-
served in the defective proband myoblasts and the p°206
transformants derived from them (Fig. 3b).
One unaffected member of the family of the proband,
related to him by a paternal lineage (R in Fig. 1), was
subjected to the same analysis as the proband. A myoblast
culture derived from a biopsy specimen from this individual,
as well as seven transformants obtained from p°206 cells by
cytoplast fusion with these myoblasts, when tested for
mitochondrial protein synthesis, revealed a normal pattern
of mitochondrial translation products (data not shown).
Respiration defect in transformants. It seemed likely that
the alteration in the protein synthesis pattern observed in the
proband myoblasts and in some of the p0 transformants
derived from them was related to the disease phenotype of
the proband. Strong support for this idea was provided by
the analysis of the respiratory properties of the transfor-
mants. In fact, of the five transformants obtained with p°206
as the recipient, the two which exhibited an altered protein
synthesis pattern (pT1 and pT4) showed a marked decrease
in 02 consumption compared with the transformant derived
from the normal individual (C4) and with the parental 143B
cells (Fig. 3c). By contrast, the three transformants which
exhibited a normal protein synthesis pattern (pT2, pT3, and
pT5) also showed a normal 02 consumption. Similarly, the
four transformants produced with clone 2 from p°206 (pT21,
pT22) or from p°701.2a (pT71, pT72), which showed a
protein synthesis defect, all exhibited a strong decrease in 02
consumption (Fig. 3d). Therefore, there appeared to be a
perfect correspondence between altered protein synthesis
pattern and respiratory deficiency in all transformants ana-
lyzed.
Two of the p0206 transformants obtained by cytoplast
fusion using myoblasts from the unaffected member of the
family (R), which were mentioned above, when tested for 02
consumption, exhibited rates very similar to that of 143B
(data not shown).
A reasonable interpretation of the respiratory deficiency
observed in the defective transformants was that it was due
to the marked decrease, as a result of the severe protein
synthesis defect, in the rate of assembly of functional
respiratory complexes which are under dual (mitochondrial
and nuclear) genetic control. This interpretation was sup-
ported by the results of measurements of activity of one such
complex, COX, in the transformants. All transformants
exhibiting a strong reduction in the rate of 02 consumption
also showed a pronounced decrease in COX activity per
milligram of mitochondrial protein, relative to the parental
143B cells (Fig. 3c and d). Similarly, all transformants with
normal 02 consumption exhibited a normal COX activity.
Normalization of the COX data for the mtDNA content of
the mitochondrial fraction, determined by dot-blot analysis
as previously described (15), yielded relative values of COX
activity in the p°206 transformants and 143B cells very
similar to the values normalized per protein content (data not
shown).
Nature of mtDNA defect in proband myoblasts. The analy-
sis of the mitochondrial translation products in the proband
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T3, and 143B cells what had been previously found in the proband muscle
Lne labeling pulses. biopsy specimen. Similar results were obtained with NcoI
b MboI
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FIG. 6. Analysis of the mtDNA of the transformants. (a) mtDNAs of pTl and pT3 do not contain any major deletions, as judged from the
identity in their XbaI restriction pattern to that of 143B mtDNA. (b) mtDNAs of pTl and pT3 share an MboI polymorphism not present in
143B mtDNA. (c) pTl mtDNA exhibits an A-to-G transition at position 8344 of the tRNALYS which is not present in pT3 mtDNA or 143B
mtDNA.
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FIG. 7. Phenotypic and genetic characterization of the cellular pedigree constructed in the present work. The solid symbols represent a
defective genotype and phenotype; the hatched symbols represent a normal genotype and phenotype. See text for details.
digests (data not shown). In another Southern blot experi-
ment involving MboI, both pT1 and pT3 mtDNA revealed a
fragment length polymorphism which distinguished the
transformant mtDNA from that of 143B.TK-, the parental
line of p°206 (Fig. 6b). It is also clear from the blots in Fig.
6 that the pTl and pT3 transformants contain approximately
equivalent amounts of mtDNA; these amounts are also
similar to the amount of mtDNA in 143B cells, previously
determined to be -9,100 molecules per cell (15).
Very recently, a report (27) has appeared linking the
occurrence of an mtDNA tRNALYS A-to-G transition at
position 8344 (1) to the MERRF syndrome. Since two
members of the proband family investigated in the present
work exhibited a full MERRF syndrome, and since the
proband myoblasts and the transformant cultures derived
therefrom showed a protein synthesis defect, it seemed
possible that the mtDNA mutation causing this defect was a
tRNALYS mutation at position 8344. Indeed, sequence anal-
ysis of the polymerase chain reaction-amplified mtDNA
fragment encompassing the tRNALYS gene from pT1, pT3,
and 143B cells revealed the A-to-G transition in pTl and its
absence in pT3 and 143B (Fig. 6c). Although a precise
quantitation could not be done, it appeared that all or at least
the great majority of pTl mtDNA was mutated and that all or
the great majority of pT3 mtDNA was wild type at position
8344. Further tests showed that the mtDNA of all transfor-
mants thus investigated which exhibited protein synthesis
and respiratory defects contained exclusively or in great
predominance G at position 8344, whereas the mtDNA of all
transformants analyzed which were phenotypically normal
contained A at the same position (Fig. 7).
DISCUSSION
Figure 7 summarizes the genetic and phenotypic charac-
teristics of the cellular pedigree constructed in the present
work with the proband myoblast clones and three different
p0 human cell lines. In this diagram, the purely or predom-
inantly defective genotype and phenotype of the original
individual myoblast clones was inferred from that of the
transformants derived therefrom. For this inference, the
plausible assumption was made, in agreement with previous
evidence (15, 30), that there was no intracellular and/or
intercellular selective advantage of mutated, nonfunctional
mtDNA over wild-type mtDNA during in vitro growth. The
correctness of this assumption was directly verified, at least
as concerns the phenotype, for one of the clones (no. 2). On
the contrary, the assignment of a wild-type genotype and
phenotype to some of the original myoblast clones did not
exclude the presence in these of a portion of mutated
mtDNA which could have been lost by selection during in
vitro growth.
Several conclusions can be drawn from the data of Fig. 7.
(i) The perfect correlation observed in the transformants
between the presence or absence of a protein synthesis
defect, an 02 consumption defect, and COX deficiency, on
the one hand, and the presence or absence of the mitochon-
drial tRNALYS gene mutation, on the other hand, shows that
the mtDNA carrying this mutation was at least in part
responsible for the defective phenotype, thus establishing a
direct link between mtDNA alteration and biochemical de-
fect. Considering the evidence recently reported concerning
the causal role of the tRNALYS mutation in the pathogenesis
of MERRF (27), it is reasonable to assume a similar role in
the proband's disease. However, one cannot exclude a
possible exacerbating role of another mtDNA mutation(s)
coexisting with the tRNALYS mutation in the genesis of the
disease investigated here.
(ii) The observation that the defective mtDNA produced
the disease phenotype in the original nuclear background of
the proband and in one genetically unrelated nuclear back-
ground, that of p°206 (or two, if the 701.2a transformants are
indeed cybrids), strongly suggests that the mtDNA carrying
the tRNALYs mutation was also sufficient by itself to produce
the disease in the proband, without the involvement of a
deleterious nuclear gene(s).
(iii) The presence of either mutated or nonmutated
mtDNA was observed in the transformants derived from the
10 proband myoblast clones investigated here. mtDNA
heteroplasmy has been previously reported in tissues or
blood in other cases of mitochondrial disease (11-13, 23, 27,
29, 34). In an analysis of clonal cultures from patients with
Kearns-Sayre syndrome, individual muscle or fibroblast
clones were found to contain either only normal mtDNA or
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a heteroplasmic population of normal and deleted mtDNA,
with occasional clones containing a high proportion (60 to
70%) of deleted mtDNA (19). In the present work, hetero-
plasmy in the myoblasts was probably to a large extent
intercellular. The data obtained, in fact, suggest that at least
50% of the myoblasts in the original myoblast culture con-
tained exclusively or in great predominance defective
mtDNA. This figure agrees roughly with the percentages of
ragged red fibers and COX-negative fibers determined in the
histochemical analysis of the muscle biopsy specimen. The
possibility of analyzing both defective and normal myoblasts
from the same individual has provided a powerful tool in the
present work to correlate the defective genotype with the
defective phenotype. Since the selection scheme used for the
isolation of transformants depended on the presence of
functional mitochondria in the cytoplasts, one must con-
clude that either the mutated mtDNA molecules allowed a
minimal level of respiratory function in the defective myo-
blasts or that these myoblasts contained a small amount of
wild-type mtDNA not detectable in the DNA sequence
analysis performed here.
It seems very likely that the tRNALYS mutation caused the
disease phenotype in the proband by severely inhibiting
mitochondrial protein synthesis in the myoblasts, and prob-
ably in other cells, and thus by drastically affecting the
assembly of respiratory complexes. In favor of this mecha-
nism of action of the tRNALYs mutation is the observation
that, although the synthesis of all polypeptides in the defec-
tive transformants was severely affected, there was a ten-
dency for this inhibition to be more complete the higher the
number of lysine residues in the polypeptides (data not
shown). The abnormal translation products observed in the
defective myoblasts and transformants derived therefrom
most probably represent incomplete polypeptides resulting
from premature termination. Consistent with this interpreta-
tion is the finding that the abnormal polypeptide migrating
faster than ND1 (Fig. 2b and 3) was precipitable by antibod-
ies directed against the NH2-terminal octapeptide of ND2
(data not shown). The observed inhibition of activity of the
respiratory chain enzyme COX is most probably a conse-
quence of the reduced rate of assembly of the COX complex,
owing to the drastically curtailed synthesis of the mtDNA-
encoded subunits I, II, and III, and is therefore consistent
with the interpretation discussed above of the mechanism of
action of the tRNALYS mutation.
The tRNALYs mutation affects a conserved nucleotide in
the TVC loop (27). This loop is known to reside, with the D
loop, at the corner of the L-shaped tridimensional structure
of the tRNAs (14) and to be involved in the interaction of the
tRNA with the ribosomal surface (24). Therefore, it seems
possible that the mutation at position 8344 affects protein
synthesis by interfering with the binding of the charged
tRNALYs to the ribosome. On the other hand, in view of
what is known about the specific interaction of the ami-
noacyl-tRNA synthetases with the tRNA molecules (21),
one cannot exclude that the mutation affects the charging of
the tRNALYS. A third possibility is that the mutation inter-
feres with the processing of the tRNALYS and thereby affects
its stability. In any case, it is clear that the availability
of established transmitochondrial cell lines carrying the
tRNALYS mutation makes the mechanism of this mutation
accessible to investigation.
The development of cellular models of mitochondrial
diseases, like that described in the present work, will open
the way to the analysis of the genetic origin of the defect in
other diseases, to the investigation of the role of mtDNA
heteroplasmy and of the nuclear background in the pene-
trance of the disease, to the molecular dissection of the
defect, and, in the future, to the establishment of rational
therapeutic approaches for the treatment of the disease.
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